Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open‐label feasibility trial. (28th November 2021)

• Record Type: Journal Article
• Authors: Goebeler, M.; Bata‐Csörgő, Z.; De Simone, C.; Didona, B.; Remenyik, E.; Reznichenko, N.; Stoevesandt, J.; Ward, E.S.; Parys, W.; de Haard, H.; Dupuy, P.; Verheesen, P.; Schmidt, E.; Joly, P.
• Is Part Of: British journal of dermatology. Volume 186:Number 3(2022)
• Page Start: 429
• Page End: 439
• Publication Date: 2021-11-28
• Subjects: Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/bjd.20782
• Languages: English
• ISSNs: 0007-0963

Abstract

Summary: Background: Pemphigus vulgaris and pemphigus foliaceus are potentially life‐threatening autoimmune disorders triggered by IgG autoantibodies against mucosal and epidermal desmogleins. There is an unmet need for fast‐acting drugs that enable patients to achieve early sustained remission with reduced corticosteroid reliance. Objectives: To investigate efgartigimod, an engineered Fc fragment that inhibits the activity of the neonatal Fc receptor, thereby reducing serum IgG levels, for treating pemphigus. Methods: Thirty‐four patients with mild‐to‐moderate pemphigus vulgaris or foliaceus were enrolled in an open‐label phase II adaptive trial. In sequential cohorts, efgartigimod was dosed at 10 or 25 mg kg −1 intravenously with various dosing frequencies, as monotherapy or as add‐on therapy to low‐dose oral prednisone. Safety endpoints comprised the primary outcome. The study is registered at ClinicalTrials.gov (identifier NCT03334058). Results: Adverse events were mostly mild and were reported by 16 of 19 (84%) patients receiving efgartigimod 10 mg kg −1 and 13 of 15 (87%) patients receiving 25 mg kg −1, with similar adverse event profiles between dose groups. A major decrease in serum total IgG and anti‐desmoglein autoantibodies was observed and correlated with improved Pemphigus Disease Area Index scores. Efgartigimod, as monotherapy or combined with prednisone, demonstrated early disease control in 28 of 31 (90%) patients after a median of 17 days. Optimized, prolonged treatment with efgartigimod in combination with a median dose of prednisone 0·26 mg kg −1 per day (range 0·06–0·48) led to complete clinical remission in 14 of 22 (64%) patients within 2–41 weeks. Conclusions: Efgartigimod was well tolerated and exhibited an early effect on disease activity and outcome parameters, providing support for further evaluation as a therapy for pemphigus. Abstract : What is already known about this topic? Efgartigimod is an Fc fragment engineered for increased affinity for the neonatal Fc receptor (FcRn) to outcompete endogenous IgG binding, thereby preventing recycling and causing increased IgG degradation. In previous phase II studies in primary immune thrombocytopenia and myasthenia gravis, as well as in a phase III study in myasthenia gravis, efgartigimod induced reductions in all IgG subclasses with corresponding clinical efficacy and was well tolerated. What does this study add? In this phase II, open‐label study of efgartigimod in patients with pemphigus vulgaris and pemphigus foliaceus, efgartigimod induced early decreases in serum total IgG, as well as disease‐specific anti‐desmoglein 1 and 3 autoantibodies, and was well tolerated. The clinical results of this study demonstrate that efgartigimod represents a well‐tolerated potential means of achieving early disease control and complete clinical remission of pemphigus while allowing early corticosteroid tapering. Linked Comment: G. Micevic et al. Br J Dermatol 2022; 186 :389–390 . Plain language summary available online